Which ONE of the following statements regarding modern drug discovery and development is CORRECT?

Question

BlackTom AI · Accepted Answer

Question restatement: Which ONE of the following statements regarding modern drug discovery and development is CORRECT?

Options analyzed:

a. Modern drug development is best carried out in a focussed manner, in isolation of regulatory and other influences from outside the development program.
- Why it’s unlikely correct: In modern drug development, regulatory expectations, external stakeholder input, and cross-functional collaboration (e.g., quality, safety, regulatory science, and external partners) are integral. Isolating from regulatory and external influences tends to reduce relevance, increase risk of non-compliance, and hamper timely approvals. This approach ignores the reality that regulatory guidance shapes trial design, data programming, and submission readiness.
- Common misconception addressed: The belief that independence from regulators yields faster or better outcomes ignores the value of early and ongoing regulatory alignment and the benefits of adaptive, risk-based approaches.

b. Modern drug development is generally hindered by the regulatory landscape, which is typically prohibitive to innovation.
- Why it’s unlikely correct: While regulation adds rigor and oversight, it does not inherently prohibit innovation. Regulatory frameworks are designed to ensure safety and efficacy, and they increasingly accommodate model-informed approaches, real-world evidence, and adaptive designs. Saying the landscape is generally prohibitive overlooks these evolving pathways and the proactive collaboration seen in successful programs.
- Common misconception addressed: Treating regulation as a barrier rather than a structured enabler misses how regulatory science advances accompany methodological innovations (e.g., MID3, adaptive trials).

c. Model-informed drug discovery and development (MID3) tools, such as population pharmacokinetic modelling (pop-PK), currently have limited utility in modern drug discovery and development, because MID3 tools are typically NOT recognised by regulatory bodies.
- Why it’s unlikely correct: MID3 tools are increasingly recognized and encouraged by regulators as part of good modeling practices to support dose finding, exposure-response analyses, and decision-making. While not every tool is universally accepted in every context, regulators have provided frameworks and expectations for model-based submissions. The blanket statement of limited utility and lack of recognition is overly pessimistic and not reflective of current practice.
- Common misconception addressed: Overestimating regulatory dismissal of MID3 ignores the growing acceptance and formal guidance surrounding model-informed approaches.

d. Modern drug discovery and development is best carried out in a manner that makes use of predictive modelling tools and is sensitive to the regulatory landscape.
- Why it’s likely correct: This option aligns with contemporary best practices. Predictive modelling (including MID3, pop-PK, PBPK, exposure-response analyses) supports dose optimization, risk mitigation, efficient design, and regulatory compliance. Being “sensitive to the regulatory landscape” means aligning modelling activities with regulatory expectations, submitting model-based justifications, and ensuring transparency and traceability of models and data.
- Common misconception addressed: Some might think modelling is optional or ancillary; in contrast, integrating predictive modelling with regulatory strategy is considered a core element of modern development.

e. Model-informed drug discovery and development (MID3) tools, such as population pharmacokinetic modelling (pop-PK), are best used in an isolated, on-off manner in modern drug discovery and development.
- Why it’s unlikely correct: An isolated or on-off application of MID3 is inconsistent with how drug development programs typically operate today. Effective use of modelling is iterative, continuous, and integrated across disciplines (discovery, nonclinical, early/toxicology, clinical pharmacology, and regulatory submissions). Isolating these tools would undermine their value in risk assessment, dose selection, and decision-making.
- Common misconception addressed: The belief that modelling can be toggled on only at specific milestones ignores the benefits of ongoing, ensemble modelling and model-informed conversations throughout the project lifecycle.

Synthesis: Across all options, (a), (b), and (e) present perspectives that either misrepresent the role of external influences, overstate regulatory friction, or advocate for isolated tool use. Option (c) is too negative about MID3 recognition by regulators given current trends. Option (d) integrates predictive modelling with regulatory awareness and aligns with current best practice: using modelling tools thoughtfully while staying attuned to regulatory expectations and requirements. The reasoning above suggests that option d best captures the correct, modern approach to drug discovery and development, though the explicit labeling of the correct option is not provided within this explanation to maintain alignment with the task’s structure.

Which ONE of the following statements regarding modern drug discovery and development is CORRECT?单项选择题

类似问题

In the image below, which letter is labelling a zygopophyseal joint surface?

Which joint is classified as primary (hyaline) cartilaginous?

What is the classification of the atlanto-occipital joint in the neck?

What is the classification of the 2nd sternocostal in the anterior trunk?

Cervical vertebrae differ from other vertebrae in that they contain ...

In the image below, which letter is labelling an area that contributes to a costovertebral joint?

In the image below, which letter is labelling the area where the supraspinous ligament attaches?

In the image below, which letter is labelling a sternocostal joint?

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单